Lab
R&B Medical Lab INC
R&B Medical Lab INC was paid $24K by Medicaid between Nov 2023 and Jun 2024, across 19 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 44% of everything it billed.
33Billing provider infoR&B MEDICAL LAB INC
WEST HILLS, CA 91304
WEST HILLS, CA 91304
33aNPI1518735703assigned 12/18/2023
33bProvider typeClinical Medical Laboratory
28Total paid$24K
24GClaims9,731
24DCodes billed19
24AFirst – last monthNov 2023 – Jun 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#392 of 561
Median peer was paid$222K
This provider vs. median0.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2023 | 385 | $734.24 | |
| 2024incomplete | 9,346 | $23K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 44% | 1,367 | 881 | $11K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 11% | 337 | 337 | $3K |
| 87507 | 11% | 335 | 335 | $3K | |
| 87481 | 8.1% | 547 | 544 | $2K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 4.8% | 371 | 371 | $1K |
| 87640 | 3.8% | 1,153 | 768 | $915.86 | |
| 87486 | 1.9% | 528 | 514 | $461.09 | |
| 87541 | 1.8% | 634 | 620 | $436.53 | |
| 87581 | 1.7% | 752 | 738 | $405.65 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.7% | 613 | 597 | $402.14 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.6% | 222 | 222 | $372.46 |
| 87641 | 1.6% | 607 | 537 | $371.70 |
7 more codes
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBIVOL, RUSLAN (PRESIDENT)